This site requires JavaScript and cookies to be enabled.

A young boy reads a book in the park laying on his stomach

For patients with ADHD, Qelbree may help bring order to a complicated disorder1‑3

The first and only ADHD nonstimulant treatment with a multimodal pharmacodynamic profile.1,4-6*

Request samples  

Patient savings  

Dosing optimization  

*The pharmacodynamic activity of viloxazine is based on non-clinical studies and the clinical significance of the data is unknown. The mechanism of action of viloxazine in the treatment of ADHD is unclear; however, it is thought to be through inhibiting the reuptake of NE.1

Qelbree is the #1 prescribed branded nonstimulant ADHD treatment‡ and is indicated for patients 6 years and older1,7

Several million prescriptions have been written for Qelbree7§ with 1 million prescriptions in 2025 alone.

†Pediatric indication approved in 2021.
‡IQVIA data, as of May 2026.
§Source: IQVIA NPA data, as of March 31, 2026.

A chef garnishes a plate
Actor portrayals.
A chef garnishes a plate

An effective, once-daily, nonstimulant treatment for ADHD1

Qelbree was proven effective in consistently improving multi-symptom ADHD in clinical trials1,7

Explore the data  

Straightforward once-daily dosing and titration to help meet the needs of patients with ADHD1

Learn about dosing  

First and only nonstimulant with a multimodal pharmacodynamic profile1,4-6*

See pharmacodynamics  

background
Pay as little as $20 for a 30 day or 90-day prescription

Savings for patients

Commercially insured patients may pay as little
as $20 for a 30-day or
90-day prescription‖

‖Terms and conditions apply.

Download savings card 

Side effects icon

A nonstimulant ADHD treatment with no evidence of abuse potential1,8,9

  • Proven safety across Phase III clinical trials in patients with ADHD ages 6 to 17 years (n=1289) and adult patients ages 18 to 65 years (n=372)1

  • No new safety signals were observed in open-label extension (OLE) trials1,7

Learn about safety 

Stay in the know

Sign up to receive Qelbree updates, additional savings information, and links to helpful resources for you and your patients.

Sign up

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.

References:

1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc. 2. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge University Press; 2021. Accessed May 15, 2026. doi:10.1017/9781108975292 3. American Psychiatric Association. Attention-deficit/ hyperactivity disorder. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text rev. American Psychiatric Association; 2022:68-77. 4. Strattera [package insert]. Indianapolis, IN: Lilly USA, LLC. 5. Intuniv [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A. 6. Clonidine extended release tablets: package insert / prescribing info. Drugs.com. Updated December 13, 2025. Accessed May 15, 2026. https://www.drugs.com/pro/clonidine-extended-release-tablets.html 7. Data on file, Supernus Pharmaceuticals, Inc. 8. Yanagita T, Wakasa Y, Kiyohara H. Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys. Pharmacol Biochem Behav. 1980;12(1):155-161. doi:10.1016/0091-3057(80)90430-x 9. Key prescription stimulant label updates. U.S. Food and Drug Administration. May 11, 2023. Accessed June 15, 2026. https://www.fda.gov/media/168050/download

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.